Patents Assigned to BONE THERAPEUTICS S.A.
  • Patent number: 11447749
    Abstract: The application discloses a method for obtaining MSC-derived cells with improved transplantation properties from MSC, the method comprising a cell size reduction step, wherein said cell size reduction step is characterized by contacting MSC or MSC-derived cells in vitro or ex vivo with heparin or a derivative or analogue thereof at a concentration of at least 0.01 IU/ml. The application further provides a method for obtaining mesenchymal stem cell-derived cells from mesenchymal stem cells (MSC) comprising contacting MSC in vitro or ex vivo with FGF-2, TGF? and at least 0.01 IU/ml heparin or a derivative or analogue thereof. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 20, 2022
    Assignee: Bone Therapeutics S.A.
    Inventors: Sandra Pietri, Xuan Mai Nguyen, Enrico Bastianelli, Sabrina Ena, Pierre-Yves Laruelle, Isabelle Tytgat
  • Patent number: 9371515
    Abstract: The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: June 21, 2016
    Assignee: Bone Therapeutics S.A.
    Inventors: Cindy Badoer, Enrico Bastianelli, Xavier Pesesse
  • Publication number: 20140093480
    Abstract: The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.
    Type: Application
    Filed: March 12, 2013
    Publication date: April 3, 2014
    Applicant: BONE THERAPEUTICS S.A.
    Inventor: Bone Therapeutics S.A.
  • Publication number: 20110262404
    Abstract: The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.
    Type: Application
    Filed: May 7, 2009
    Publication date: October 27, 2011
    Applicant: BONE THERAPEUTICS S.A.
    Inventors: Cindy Badoer, Enrico Bastianelli, Xavier Pesesse
  • Publication number: 20110064692
    Abstract: The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of diseases and conditions associated with immunodeficiency or immunosuppression.
    Type: Application
    Filed: May 8, 2009
    Publication date: March 17, 2011
    Applicant: BONE THERAPEUTICS S.A.
    Inventors: Valentina Albarani, Enrico Bastianelli, Cindy Badoer, Xavier Pesesse
  • Publication number: 20100272696
    Abstract: The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases.
    Type: Application
    Filed: December 19, 2008
    Publication date: October 28, 2010
    Applicant: BONE THERAPEUTICS S.A.
    Inventors: Enrico Bastianelli, Cindy Badoer, Christelle Bizimungu, Xavier Pesesse